Paulina Hill, Sanofi Ventures

Board Member

Paulina joined Sanofi Ventures in 2022 with a background in early stage biotech investing. Prior to joining Sanofi, Paulina was a principal on the investment team at Omega Funds where she served as the board director/observer for Scorpion Therapeutics, Arrakis Therapeutics, and IFM, and additionally led or co-led Omega’s investments in Theseus, Ikena, Synthekine, and Vanqua Bio.

Prior to Omega Funds, Paulina began her career with Polaris Partners. Paulina served on the boards of Kala Pharmaceuticals, Neuronetics, Lyra Therapeutics, Microchips Biotech, Arsenal Medical, and CAMP4 Therapeutics, where she was the founding CEO. Paulina completed her postdoctoral fellowship in Robert Langer’s lab at MIT. Paulina completed her PhD in Molecular Medicine from Wake Forest School of Medicine.